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Abstract A mitochondrial tRNALys gene mutation at nucleotide
position 8344 is responsible for the myoclonus epilepsy associated
with ragged-red fibers (MERRF) subgroup of mitochondrial
encephalomyopathies. Here, we show that normally modified
uridine at the anticodon wobble position remains unmodified
in the purified mutant tRNALys. We have reported a similar
modification defect at the same position in two mutant
mitochondrial tRNAsLeu(UUR) in another subgroup, mitochon-
drial myopathy, encephalopathy, lactic acidosis and stroke-like
episodes (MELAS), indicating this defect is common in the two
kinds of tRNA molecules with the respective mutations of the two
major mitochondrial encephalomyopathies. We therefore suggest
the defect in the anticodon is responsible, through the transla-
tional process, for the pathogenesis of mitochondrial diseases.
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1. Introduction
Point mutations as well as large-scale deletions in mito-
chondrial DNA (mtDNA) are associated with a wide spec-
trum of human diseases caused by mitochondrial dysfunction,
and most pathogenic mutant mtDNAs coexist with wild-type
mtDNA in a heteroplasmic manner [1]. In particular, point
mutations are frequently found in mitochondrial tRNA genes
[2]. Among the tRNA point mutations reported so far, an A
to G transition at nucleotide position (np) 8344 located in the
T8C arm of the mitochondrial tRNALys gene is found in 90%
of patients with myoclonus epilepsy associated with ragged-
red ¢bers (MERRF) [3], which is one of the most well-studied
mitochondrial encephalomyopathies [4]. In addition, a point
mutation at either np 3243 or 3271 of the tRNALeu(UUR)
gene is responsible for mitochondrial myopathy, encephalo-
pathy, lactic acidosis and stroke-like episodes (MELAS), an-
other major subgroup of the mitochondrial encephalomyopa-
thies [5^8], which is distinguishable from MERRF by its
clinical features [4]. It remains unknown why the phenotypes
are distinct, corresponding to particular tRNA genes with
point mutations.
By constructing cybrid cells in which mutant mtDNA de-
rived from patients was intercellularly transferred into human
cells lacking mtDNA (b0 cells), these three mutations (at np
8344, 3243 and 3271) have been demonstrated to be directly
involved in either decreased respiratory activity or oxygen
consumption without nuclear gene involvement [9^13]. How-
ever, just how a mutation in a tRNA gene causes the mito-
chondrial dysfunction that gives rise to mitochondrial disease
is little understood. In the case of MERRF, mutant cybrid
cells in which the ratio of mtDNA with the 8344 mutation
exceeded 90% exhibited severely impaired mitochondrial pro-
tein synthesis and produced abortive polypeptides [13]. It has
been proposed that an approximately 50% reduction in ami-
noacyl-tRNALys accounts for these defects, resulting in de-
creased respiratory activity. Although this model is attractive,
it is also plausible that abnormal functioning of tRNA mol-
ecules with a pathogenic mutation is involved in the mito-
chondrial disease.
Here, we demonstrate that the 8344 mutation in tRNALys
leads to lack of the modi¢cation in the wobble nucleotide.
Recently, we puri¢ed the two mutant tRNAsLeu(UUR) with
the 3243 and the 3271 MELAS mutations from the respective
cybrid cells and found that both were de¢cient in the modi¢-
cation of uridine at the ¢rst position of the anticodon [14].
The fact that the lack of the modi¢cation in the pathogenic
mutant tRNA molecules is observed in both MERRF and
MELAS suggests that this defect could be the cause of the
pathogeneses of these two major mitochondrial encephalo-
myopathies. Since the modi¢cation is essential for accurate
and e⁄cient decoding in mitochondrial translation, investiga-
tion of the defect might shed light on the pathogenesis of
MERRF at the translational level.
2. Materials and methods
2.1. Cybrid cell lines
A mutant cybrid cell line which possesses mtDNA with the A8344G
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mutation was a kind gift from Dr. J.-I. Hayashi of Tsukuba Univer-
sity. This cybrid cell line was constructed by the intercellular transfer
of patient mtDNA to b0 HeLa cells (EB8) and isolation of cybrid
clones as described [15,16]. The mutant mtDNA was accumulated
by subcloning and the ME1-4 cell line exclusively possessing mtDNA
with the A8344G mutation was obtained. The Ft2-11 cell line for use
as a wild-type control was obtained by fusing EB8 cells with
enucleated fetal human ¢broblasts as described [16]. The cells were
cultured in normal medium (Dulbecco’s modi¢ed Eagle’s medium/
F-12 (1:1) (Gibco BRL), 10% fetal calf serum).
2.2. Puri¢cation of tRNALys from cybrid cells by solid-phase probing
About 300^1000 A260 units (the actual number varied depending on
the cell line) of total RNA were extracted from approximately 109
semi-con£uent cultured cybrid cells by Isogen (Nippon Gene, Toya-
ma, Japan). Total RNA was incubated at 37‡C for 3 h in 50 mM
Tris^HCl (pH 9.5) to discharge amino acids from the tRNAs. The
deacylated total RNA preparation was adjusted to pH 7.5 and frac-
tionated on a DEAE-Sepharose Fast Flow (Amersham Pharmacia
Biotech) column (1U45 cm) with a linear gradient of NaCl and
MgCl2, between 250 and 500 mM and between 8 and 16 mM, respec-
tively, in a bu¡er containing 20 mM Tris^HCl (pH 7.5). Fractions
enriched with tRNALys were monitored by dot hybridization with
an oligonucleotide probe speci¢c for mitochondrial tRNALys :
5P-TCACTGTAAAGAGGTGTTGG-3P (not including the mutation
position). tRNALys was puri¢ed by solid-phase probing using a
3P-biotinylated oligonucleotide with a sequence identical to that
used for the dot hybridization, which was immobilized on streptavidin
agarose (Gibco BRL) as described [17]. The tRNALys was further
puri¢ed by gel electrophoresis.
2.3. Sequence determination of wild-type and mutant tRNAsLys
including modi¢cations
Puri¢ed tRNALys with or without the 8344 mutation was sequenced
by a combination of the methods of Donis-Keller [18] and Kuchino et
al. [19]. For Donis-Keller’s method [18], the homogeneous tRNA was
labeled at the 5P-terminal with [Q-32P]ATP (110 TBq/mmol, Amersham
Pharmacia Biotech) and T4 polynucleotide kinase (Toyobo, Osaka,
Japan). The nucleotide-speci¢c RNases used for restricted digestion of
tRNA were RNase T1 (Amersham Pharmacia Biotech), U2 (Seikaga-
ku Kogyo, Tokyo, Japan), PhyM (Amersham Pharmacia Biotech)
and CL3 (Boehringer Mannheim). For the method of Kuchino et al.
[19], each nucleotide in the tRNA was analyzed by two-dimensional
thin-layer chromatography (2D-TLC) using two di¡erent solvent sys-
tems. Solvent system A consisted of isobutyric acid/concentrated am-
monia/H2O (66:1:33 by volume) in the ¢rst dimension, and 2-prop-
anol/HCl/H2O (70:15:15 by volume) in the second. In solvent system
B, the ¢rst dimension was the same as that used for system A, but 0.1
M sodium phosphate (pH 6.8)/ammonium sulfate/1-propanol (100
ml:60 mg:2 ml) was used for the second dimension.
2.4. Identi¢cation of tRNALys anticodon ¢rst letter by restrictive
digestion with RNase H
Restrictive digestion at the anticodon ¢rst letter was done according
to the literature [20]. Using a splint oligonucleotide primer composed
of DNA and RNA (5P-rCUrCUUrArAUrCUUUrArArCUUrAr-
AAAGGTTA-3P) and possessing a cleavage site between positions
33 and 34 (anticodon ¢rst letter) of tRNALys, 0.005 A260 unit homo-
geneous wild-type tRNALys or mutant tRNALys(A8444G) was incu-
bated at 65‡C for 10 min and then cooled down to 35‡C for annealing
in a bu¡er consisting of 40 mM Tris^HCl (pH 7.9), 1 mM DTT, 4%
glycerol and 0.003% BSA. Magnesium chloride was added to the
mixture up to a ¢nal concentration of 4 mM and the reaction was
carried out at 30‡C for 1 h by addition of RNase H (Takara Shuzo,
Kyoto, Japan). A cleaved 3P-half fragment was obtained by gel elec-
trophoresis puri¢cation. The fragment was labeled at the 5P-terminal
with 32P and digested completely by RNase P1. The 32P-labeled nu-
cleotide (anticodon ¢rst letter nucleotide) derived from the tRNA
fragment was analyzed by 2D-TLC using two di¡erent solvent sys-
tems according to the method of Kuchino et al. [19].
3. Results
3.1. Defect in the modi¢cation at the anticodon ¢rst position of
tRNALys with the A8344G mutation
We puri¢ed the wild-type and mutant tRNAsLys in amounts
su⁄cient for structural analysis from mass cultures of cybrid
cells and determined their nucleotide sequences, including
modi¢ed nucleotides, by a combination of the methods of
Donis-Keller [18] and Kuchino et al. [19]. Restrictive digestion
with RNase H was also employed to analyze the anticodon
wobble nucleotide modi¢cation [20]. Sequence analysis by Do-
Fig. 1. Sequence analysis of human mitochondrial tRNALys and MERRF patient-derived tRNALys with the A to G 8344 mutation. (a, b) Se-
quencing ladders obtained by Donis-Keller’s method [18] for wild-type and mutant tRNAsLys from each cybrid clone in regions around the
point mutation (a) and the anticodon loop (b). -E, Al, T1, U2, PM and CL indicate no treatment and digestion by alkali, RNase T1 (speci¢c
for G), RNase U2 (for AsG), RNase PhyM (for A and U) or RNase CL3 (for C), respectively. In (b), U and U*, respectively, indicate un-
modi¢ed and modi¢ed uridine. (c) 2D-TLC patterns of a 32P-labeled nucleotide at the anticodon wobble position obtained from wild-type and
mutant tRNAsLys by restrictive digestion with RNase H as described in Section 2. The upper panels show the results with solvent system A
and the lower panels those with solvent system B. pU, pA, pG, pC and pU* indicate the position of each nucleotide. Arrowheads show the po-
sition of the modi¢ed uridine (pU*). (d) 2D-TLC patterns of a 32P-labeled nucleotide at the anticodon wobble position obtained from wild-
type tRNALeu(UUR) [14]. tRNALeu(UUR) and tRNALys are seen to have the identical modi¢ed uridine at the anticodon ¢rst position.
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nis-Keller’s method [18] revealed that tRNALys from ME1-4
cybrid cells harboring the MERRF 8344 mutant mtDNA had
an A to G transition in the T8C-loop (tRNALys(A8344G))
(Fig. 1a), thereby demonstrating the existence of the mutant
tRNA molecule in the mitochondria of the mutant cybrid
cells. The sequencing ladders also indicate that the tRNA
with the 8344 mutation was puri¢ed to homogeneity (Fig.
1a). The sequencing ladders in Fig. 1b clearly show that the
¢rst letter of the anticodon of the wild-type tRNALys was
resistant against RNase PhyM (A- or U-speci¢c) digestion,
and an irregular band pattern was observed at this position
in the alkaline-treated lanes. These features suggest that the
¢rst nucleotide of the anticodon of wild-type tRNALys is a
modi¢ed uridine, as has been reported [21]. Recently, by
means of 2D-TLC using two di¡erent solvent systems togeth-
er with high-performance liquid chromatography/electrospray
ionization mass spectrometry, we revealed that human and
bovine mitochondrial tRNAsLeu(UUR) have the same novel
modi¢ed uridine at the wobble position [14,22]. In the present
study, the nucleotide derived from the anticodon wobble po-
sition of the wild-type tRNALys was obtained by restrictive
digestion with RNase H as described in Section 2 [20], and
was developed on 2D-TLC with the same solvent systems [19].
The mobility of this nucleotide di¡ered from that of unmodi-
¢ed uridine or the uridine derivatives reported so far (Fig. 1c)
[23], but was exactly the same as the nucleotide obtained from
the wobble position of mitochondrial tRNALeu(UUR) (Fig.
1d). Therefore, both tRNALys and tRNALeu(UUR) have the
identical novel uridine modi¢cation.
In striking contrast, PhyM digestion of the mutant tRNALys-
(A8344G) gave a discrete band at the wobble position and al-
kaline-treated ladders were normal around the position (Fig.
1b), suggesting that uridine at this position was not modi¢ed
in the mutant cybrid cells. Lack of the modi¢cation at the
anticodon wobble nucleotide in the mutant tRNALys was
demonstrated as described above (Fig. 1c), clearly proving
that the major spot corresponds to genuine uridine [23]. All
the nucleotides in tRNALys were analyzed by 2D-TLC using
the method of Kuchino et al. [19] to identify those that were
modi¢ed, which were found to be the following already
known nucleosides: 1-methyladenosine (m1A), 2-methylgua-
nosine (m2G), pseudouridine (8) and N6-threoninocarbonyl-
adenosine (t6A) (Fig. 2) [23]. No di¡erences were observed in
respect of the other modi¢ed nucleotides of the wild-type and
mutant tRNAsLys, indicating a speci¢c lack of the modi¢ca-
tion at the wobble position of the mutant tRNALys.
Since mitochondrial tRNALys and tRNALeu(UUR) in the
wild-type cells have the identical modi¢ed uridine at the wob-
ble position, we analyzed the modi¢cation in the tRNALeu-
(UUR) that occurs in 8344 mutant ME1-4 cybrid cells. In the
sequencing ladders in Fig. 3, the ¢rst letter of the anticodon of
tRNALeu(UUR) puri¢ed from the mutant cells, as well as that
of the wild-type cells, is resistant to RNase PhyM digestion
and there is unusual mobility in the alkaline-treated lanes at
this position. These features strongly suggest that modi¢ca-
tion of the uridine residue normally occurs at the wobble
position of the tRNALeu(UUR) even in the mutant cells.
Therefore, lack of the modi¢cation in the mutant tRNALys
is apparently due to the direct e¡ect of the point mutation,
and not to the indirect e¡ect of mitochondrial dysfunction.
4. Discussion
Enriquez et al. made a detailed analysis of the MERRF np
8344 mutation [13]. They surmised that the approximately
50% decrease in aminoacyl-tRNALys observed in mutant cells
caused a severe reduction in mitochondrial protein synthesis
and the production of aberrant translation products, resulting
in the respiratory chain defect. In the cases of the 3243 and
3271 mutations in the tRNALeu(UUR), however, we estimated
the total amount of leucyl-tRNALeu(UUR) with the mutation
to be less than 30% that of the wild-type [14], and no signi¢-
cant decrease in protein synthesis was observed [12,24]. Also,
in the case of chronic progressive external ophthalmoplegia,
Hayashi et al. found that progressive inhibition of mitochon-
drial translation as well as a reduction in cytochrome c oxi-
dase activity occurred in cybrid cells only when v-mtDNA
(mutant mtDNA with large-scale deletions, including ¢ve
tRNA genes) accumulated to over 60% of the total mtDNA,
i.e. there was a 60% reduction in the ¢ve tRNAs and more
than 60% of the ¢ve respective aminoacyl-tRNAs was missing
[16]. Taking these ¢ndings together, a 50% decline in only one
aminoacyl-tRNA seems inadequate to completely explain
the biochemical pathology of MERRF. Furthermore, we ob-
served neither instability nor a decrease in the steady-state
Fig. 2. Cloverleaf structures of human mitochondrial tRNAsLys
from wild-type cells (left) and from MERRF patient-derived cells
with the A8344G mutation (right). U* indicates the modi¢ed uridine
and U on a round black background, unmodi¢ed uridine. G on a
square black background represents the point mutation. The other
modi¢ed nucleosides were determined according to the methods of
Donis-Keller [18] and Kuchino et al. [19] : 1-methyladenosine (m1A),
2-methylguanosine (m2G), pseudouridine (8) and N6-threoninocar-
bonyladenosine (t6A).
Fig. 3. Con¢rmation of the presence of modi¢ed uridine at the wob-
ble position of mitochondrial tRNALeu(UUR) in the mutant ME1-4
cybrid clone. Sequencing ladders obtained by Donis-Keller’s method
[18] of tRNAsLeu(UUR) from mutant cells and wild-type cells in the
region around the anticodon loop. Unusual upper shifts of bands in
the alkaline ladders and resistance against RNase PhyM digestion
were similarly observed at the wobble position of the tRNALeu-
(UUR) from the mutant cells and that from the wild-type cells,
indicating that tRNAsLeu(UUR) from both the mutant and wild-
type cells have modi¢ed uridine at the position. The wobble posi-
tions are indicated by arrows.
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amount of the tRNALys with the MERRF mutation as com-
pared with its wild-type counterpart in the respective cybrid
cells (data not shown).
Since the uridine at the anticodon ¢rst position of
tRNALeu(UUR) in mitochondria of mutant MERRF cybrid
cells was con¢rmed to undergo the modi¢cation, we consider
that the lack of the modi¢cation in the tRNALys with the
8344 mutation is not caused by a defect in or loss of the
modi¢cation enzyme(s) in the ME1-4 cybrid cells but by the
point mutation in the T8C arm of the MERRF mutant
tRNALys.
In view of our previous discovery that the nucleotide mod-
i¢cation at the ¢rst letter of the anticodon is de¢cient in the
two mutant mitochondrial tRNAsLeu(UUR) derived from pa-
tients with MELAS [14], we considered that a similar modi¢-
cation abnormality was likely to occur in tRNALys with the
MERRF mutation. To con¢rm this, we puri¢ed the wild-type
and mutant tRNAsLys to homogeneity in amounts su⁄cient
for structural analysis from mass cultures of cybrid cells
grown in a complete and non-isotopic medium. Sequencing
of the tRNAs revealed that tRNALys with the 8344 mutation
is in fact de¢cient in the modi¢cation at the anticodon wobble
position. The modi¢ed uridine is identical to that at the anti-
codon ¢rst position of tRNALeu(UUR). This is the ¢rst ac-
count of a common defect in the two kinds of tRNA mole-
cules with the respective pathogenic mutations of two major
mitochondrial encephalomyopathies. The fact that the three
mutant tRNAs possess this common defect in their post-tran-
scriptional modi¢cation at the wobble position leads us to
speculate that the defect is a strong candidate for being at
the root of both MERRF and MELAS pathogeneses.
Modi¢cations at the anticodon wobble position play an
important role in the decoding of cognate codons. One pos-
sible explanation is that mutant tRNALys lacking the modi¢ed
base cannot decode its cognate codons (AAA and AAG) e⁄-
ciently, consequently disturbing natural protein synthesis in
mitochondria. As codon-anticodon base pairing of the mito-
chondrial tRNALys consists of A-U and G-U pairs which are
relatively weak as compared to the G-C pair, the modi¢ed
uridine at the wobble position might contribute to the stability
of the codon-anticodon base pairing. If this is the case, it
could explain the reported decrease in protein synthesis and
the production of aberrant polypeptides [13] even without a
reduction in the amount of tRNALys. Another possibility,
which is based on the mitochondrial wobble rule [25^29]
and in vitro translation experiments [30,31], is that an un-
modi¢ed uridine at the wobble position of the mutant
tRNA can recognize all four bases at the third letter of the
codon (AAN; N = A, G, U and C), leading to misincorpora-
tion. Whatever the mechanism, lack of the mutant tRNALys
anticodon modi¢cation could signi¢cantly a¡ect the mito-
chondrial translation process even when the mutation ratio
does not exceed the previously proposed threshold [11,13].
Our proposal does not contradict the fact that patients ex-
press clinical symptoms when the proportion of the mutant
mtDNA in a tissue, such as muscle, is substantially less than
the threshold proposed previously, which leads us to speculate
that the modi¢cation defect in tRNALys with the 8344 muta-
tion plays a signi¢cant role in the pathogenesis of MERRF.
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